Abbvie's Trading Volume Drops 38.76% to $1.086 Billion, Ranks 58th in Market

Abbvie's trading volume on May 7, 2025, was $1.086 billion, a significant decrease of 38.76% from the previous day, placing it 58th in the day's stock market rankings. Abbvie's stock price increased by 0.50%.

Abbvie has announced that it will be acquiring Allergan, a move that is expected to significantly boost its portfolio of dermatology and aesthetics products. This acquisition is part of Abbvie's strategy to diversify its revenue streams and reduce its reliance on its blockbuster drug, Humira. The deal is expected to close in the second half of 2025, subject to regulatory approvals.

Abbvie has also announced that it will be investing $1 billion in research and development over the next five years. This investment is aimed at developing new treatments for rare diseases and expanding its pipeline of innovative medicines. The company has also announced that it will be partnering with several academic institutions to conduct clinical trials for these new treatments.

Abbvie has also announced that it will be expanding its manufacturing capabilities in the United States. The company has announced plans to build a new manufacturing facility in North Carolina, which is expected to create over 1,000 jobs in the region. This expansion is part of Abbvie's strategy to increase its production capacity and reduce its dependence on foreign suppliers.